Fiche publication
Date publication
janvier 2025
Journal
JHEP reports : innovation in hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre
Tous les auteurs :
Xia D, Bai W, Wang Q, Chung JW, Adhoute X, Kloeckner R, Zhang H, Zeng Y, Sripongpun P, Nie C, Kim SU, Huang M, Hu W, Ding X, Yin G, Li H, Zhao H, Bronowicki JP, Li J, Li J, Zhu X, Wu J, Zhang C, Gong W, Li Z, Lin Z, Xu T, Yin T, Anty R, Song J, Shi H, Shao G, Ren W, Zhang Y, Yang S, Zheng Y, Xu J, Wang W, Zhu X, Fu Y, Liu C, Kaewdech A, Ding R, Zheng J, Liu S, Yu H, Zheng L, You N, Fan W, Zhang S, Feng L, Wang G, Zhang P, Li X, Chen J, Zhang F, Shao W, Zhou W, Zeng H, Cao G, Huang W, Jiang W, Zhang W, Li L, Feng A, Wang E, Wang Z, Han D, Lv Y, Sun J, Ren B, Xia L, Li X, Yuan J, Wang Z, Luo B, Li K, Guo W, Yin Z, Zhao Y, Xia J, Fan D, Wu K, Bettinger D, Vogel A, Han G,
Lien Pubmed
Résumé
Current prognostic models for patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE) are not extensively validated and widely accepted. We aimed to develop and validate a continuous model incorporating tumor burden and biology for individual survival prediction and risk stratification.
Mots clés
Alpha-fetoprotein, Hepatocellular carcinoma, Risk stratification, Transarterial chemoembolization, Tumor burden
Référence
JHEP Rep. 2025 01;7(1):101216
